Walnut Hull

Green hull polyphenols: NF-κB/apoptosis/proliferation/invasion mod, antioxidant ↑; preclinical in GI/breast/prostate/bone.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Preclinical — Strong in vitro/animal activity across tumor models; no therapeutic human trials yet.Juglone-rich hullGreen walnut extract

Forms: Green hull powder (500 mg capsules) · Juglone-standardized extract (10-20 mg)

Educational only, not medical advice. OncoForge makes no claim that Walnut Hull treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Polyphenol-rich green walnut hull (notably the quinone juglone) suppresses pro-inflammatory NF-κB signaling, halts the cell cycle, and triggers intrinsic apoptosis; it also limits migration/invasion and provides antioxidant capacity in normal tissue. Anticancer evidence is preclinical across GI, breast, prostate, and bone models.

Evidence at a glance

Tier 1 · labGastricBreastProstateOsteosarcoma

In vitro NF-κB/apoptosis robust; animal GI/breast/prostate delays; no oncology trials; safety from topical use.

How it may work

Juglone and co-polyphenols downshift NF-κB/STAT3 and PI3K-AKT signaling, increase ROS stress within tumor cells, and prime mitochondrial apoptosis (Bax/Bcl-2 shift, caspases). Additional actions include G0/G1 or G2/M arrest via CDK modulation and reduced MMP-2/9 activity/EMT traits limiting invasion. Antioxidant effects are context-dependent (protective in normal cells, pro-oxidant tipping in tumors).

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

NF-κB↓Inflammatory signaling suppression
Apoptosis↑Mitochondrial intrinsic pathway
Proliferation↓Cell-cycle arrest
Invasion/MMP↓EMT and migration reduction
Antioxidant↑Normal tissue protection

NF-κBApoptosisProliferationInvasion/MMPAntioxidant

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Doxorubicin: Cytotoxicity enhancement in breast cancer.
Curcumin: Antioxidant complement in colon cancer.
Resveratrol: Inflammation reduction in tumor growth.
Quercetin: Anti-proliferative synergy in prostate.

Overlapping mechanisms

NF-κB ↓: Overlaps curcumin; inflammation ceiling.
Apoptosis ↑: Redundant with juglone analogs; caspase saturation.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Gi UpsetMineral BindingSkin Irritation

Potential interactions

iron_supplementsSeparateLowTheoreticalTannin chelation reduces uptake.
chemo (anthracyclines)SynergizeLowTheoreticalApoptosis enhancement.
DoxorubicinSynergizeLowTheoreticalCytotoxicity boost in breast cancer.

Timing

With-meal: Reduces GI irritation.
BID: Divided for steady exposure.

References

Research

No published studies for Walnut Hull yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Walnut Hull depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 500–2000 mg/day (po) divided BID; with meals, Preclinical 50-200 mg/kg; human extrapolated 500-1000 mg/day green hull; short-term cycles; monitor GI/minerals..

Trials studying Walnut Hull

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar